Literature DB >> 20659810

Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?

Hans G Kress.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659810     DOI: 10.1016/j.ejpain.2010.06.017

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


× No keyword cloud information.
  42 in total

Review 1.  Tapentadol extended release: in adults with chronic pain.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

Review 2.  Opioid-induced bowel dysfunction.

Authors:  Gyanprakash A Ketwaroo; Vivian Cheng; Anthony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2013-09

3.  [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].

Authors:  M Merker; G Dinges; T Koch; P Kranke; A M Morin
Journal:  Schmerz       Date:  2012-02       Impact factor: 1.107

4.  On the Molecular Basis Underlying the Metabolism of Tapentadol Through Sulfation.

Authors:  Ahsan F Bairam; Mohammed I Rasool; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 5.  Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach.

Authors:  Spencer Dorn; Anthony Lembo; Filippo Cremonini
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

6.  Tapentadol in neuropathic pain cancer patients: a prospective open label study.

Authors:  Edvina Galiè; Veronica Villani; Irene Terrenato; Andrea Pace
Journal:  Neurol Sci       Date:  2017-07-11       Impact factor: 3.307

Review 7.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

8.  [Prolonged-release tapentadol for phantom pain. A case series].

Authors:  K-U Kern; P Bialas; D Fangmann
Journal:  Schmerz       Date:  2013-04       Impact factor: 1.107

Review 9.  The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Y Kögel
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR.

Authors:  Andrew Paris; Chris M Kozma; Wing Chow; Anisha M Patel; Samir H Mody; Myoung S Kim
Journal:  Am Health Drug Benefits       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.